University of Toronto, Canada
Assistant Professor and Scientist
Dr. Hagar Labouta is a Scientist at Unity health Toronto and Assistant Professor at University of Toronto at Leslie Dan Faculty of Pharmacy and Institute of Biomedical Engineering. She has research experience in nanomedicine, drug delivery, and biomedical engineering. Before joining the University of Toronto, she was an Assistant Professor at the University of Manitoba. She got her Ph.D. in pharmaceutical nanotechnology from Saarland University (Germany) and completed several Postdocs at Helmholtz institute (Germany), and University of Calgary (Canada). Her team is using microfluidics to design lipid-based nanoparticles for the aim of breaching biological barriers with special focus on applications related to Women’s Health. To ensure clinical translation of the novel therapies designed in her lab, her team develops humanized organ-on-a-chip models for preclinical evaluation of nanoparticles. Her lab is well-funded by national and international funds. Dr. Labouta has a strong publication record and is a co-inventor on an international patent for the development of nanosystems for intracellular targeting. She has also worked with the WHO on two health-related projects. She has won several awards including Member of the Year Award from the Controlled Release Society (USA), Interstellar Award from New York Academy of Sciences (USA), Innovation and Career Development Award by the Biomedical Engineering Society (USA), Apotheker Jacob Prize (Germany) and curriculum award for the Nanoscience Minor Program (Canada). Dr. Labouta serves as an Associate Editor in the Drug Delivery and Translational Research (DDTR) and is on the editorial board of Journal of Controlled Release. She was an invited speaker, including as a keynote speaker, at several conferences in the USA, Australia, Canada, etc.
